A 3-gene prognostic model, composed of LY6D, BCAT1, and ITGB6, constructed with differentially expressed genes (DEGs) between the PAAD subtypes, could be used to evaluate the prognosis of patients with PAAD. The gene discussed is BCAT1; the disease is pancreatic adenocarcinoma.